Literature DB >> 25585782

Are we appropriately selecting therapy for patients with cervical cancer? Longitudinal patterns-of-care analysis for stage IB-IIB cervical cancer.

Julie A Carlson1, Chad Rusthoven2, Peter E DeWitt3, Susan A Davidson4, Tracey E Schefter2, Christine M Fisher2.   

Abstract

PURPOSE: We performed a patterns-of-care analysis evaluating the effects of newer technology and recent research findings on treatment decisions over 26 years to determine whether patients with cervical cancer are being appropriately selected for treatment to optimize the therapeutic ratio. METHODS AND MATERIALS: A retrospective analysis was conducted using the Surveillance, Epidemiology and End Results (SEER) program from 1983 to 2009. We identified 10,933 women with stage IB-IIB cervical carcinoma.
RESULTS: Of the 10,933 subjects identified, 40.1% received surgery, 26.8% received radiation (RT), and 33.1% received surgery plus RT. RT use increased after 2000 compared to prior to 2000, with a corresponding decrease in surgery and surgery plus RT. Among patients with risk factors including tumor size >4 cm, positive parametria, and positive lymph nodes, declining use of surgery plus RT was observed. However, 23% of patients with tumors >4 cm, 20% of patients with positive parametria, and 55% of node-positive patients continued to receive surgery plus RT as of 2009. Factors associated with increased use of surgery plus RT included patient age <50 and node-positive status.
CONCLUSIONS: In this largest patterns-of-care analysis to date for patients with locally advanced cervical cancer, we found a substantial proportion of patients continue to undergo surgery followed by radiation, despite randomized data supporting the use of definitive radiation therapy, with lower morbidity than surgery and radiation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25585782     DOI: 10.1016/j.ijrobp.2014.07.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Prognostic factors in Asian and white American patients with cervical cancer, considering competing risks.

Authors:  Y Hou; S Guo; J Lyu; Z Lu; Z Yang; D Liu; Z Chen
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

2.  Retrospective analysis of patients with carcinoma cervix in a rural/semi-urban setting in Western India.

Authors:  Ranvijay Singh; Nishitha Shetty; Maryam Naveed; Suraj B Pawar; Sindu Iska; Navya Reddy Alugubelli
Journal:  Indian J Med Paediatr Oncol       Date:  2016 Jan-Mar

3.  Carcinoma of the cervix in elderly patients treated with radiotherapy: patterns of care and treatment outcomes.

Authors:  Ming Yin Lin; Srinivas Kondalsamy-Chennakesavan; David Bernshaw; Pearly Khaw; Kailash Narayan
Journal:  J Gynecol Oncol       Date:  2016-07-19       Impact factor: 4.401

4.  Feasibility of radical hysterectomy in women with FIGO stage IIB cervical cancer: an observation study of 10-year experience in a tertiary center.

Authors:  Lei Yuan; Jiaqi Guo; Xiaochun Zhang; Mo Chen; Congjian Xu; Liangqing Yao
Journal:  Onco Targets Ther       Date:  2018-09-19       Impact factor: 4.147

5.  Effect of radiotherapy on the survival of cervical cancer patients: An analysis based on SEER database.

Authors:  Jian Yang; Haoyang Cai; Zhi-Xiong Xiao; Hangyu Wang; Ping Yang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 6.  Profile of bevacizumab and its potential in the treatment of cervical cancer.

Authors:  Christine M Fisher; Tracey E Schefter
Journal:  Onco Targets Ther       Date:  2015-11-19       Impact factor: 4.147

7.  Quality indicators for cervical cancer care in Japan.

Authors:  Tomone Watanabe; Mikio Mikami; Hidetaka Katabuchi; Shingo Kato; Masanori Kaneuchi; Masahiro Takahashi; Hidekatsu Nakai; Satoru Nagase; Hitoshi Niikura; Masaki Mandai; Yasuyuki Hirashima; Hiroyuki Yanai; Wataru Yamagami; Satoru Kamitani; Takahiro Higashi
Journal:  J Gynecol Oncol       Date:  2018-11       Impact factor: 4.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.